Company Directory > Pharma > PRN Pharmacal
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of PRN Pharmacal and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR

PRN Pharmacal

Pensacola, Florida, USA
VISIT WEBSITE
PRN Pharmacal is a veterinary pharmaceutical company dedicated to developing specialized therapeutics that address unmet, underserved, and overlooked needs in animal health. Founded in 1978, the company focuses on niche products, drug therapies, and nutritional supplements for cats, dogs, and horses. Operating as a division of Pegasus Laboratories, Inc., the company is employee-owned and maintains a commitment to high-quality manufacturing standards (cGMP). In addition to its branded product portfolio, it serves as a contract development and manufacturing organization (CDMO) for the animal health industry.
CLASSIFICATION
Company Type:Pharma
Industry:Pharmaceuticals
Sub-Industry:Veterinary Pharmaceuticals
SIZE & FINANCIALS
Employees:51-200
Founded:1978
Ownership:subsidiary
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Nutritional therapeutics
Active Trials:0
Trial Phases:-
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:PBI-Gordon Companies, Inc.
Acquired By:PBI-Gordon Companies, Inc.
Key Partnerships:Becton, Dickinson & Co. (BD) - surgical and medical device distribution
COMPETITION
Position:Niche Player
Competitors:Zoetis, Elanco, Bimeda, Ceva Animal Health
LEADERSHIP
Key Executives:
Donna Logan - General Manager
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with PRN Pharmacal. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.